title: Caloric restriction and chronic inflammatory diseases.
abstract: A reduction in calorie intake [caloric restriction (CR)] appears to consistently decrease the biological rate of aging in a variety of organisms as well as protect against age-associated diseases including chronic inflammatory disorders such as cardiovascular disease and diabetes. Although the mechanisms behind this observation are not fully understood, identification of the main metabolic pathways affected by CR has generated interest in finding molecular targets that could be modulated by CR mimetics. This review describes the general concepts of CR and CR mimetics as well as discusses evidence related to their effects on inflammation and chronic inflammatory disorders. Additionally, emerging evidence related to the effects of CR on periodontal disease in non-human primates is presented. While the implementation of this type of dietary intervention appears to be challenging in our modern society where obesity is a major public health problem, CR mimetics could offer a promising alternative to control and perhaps prevent several chronic inflammatory disorders including periodontal disease.
authors.affiliation: Center for Oral Health Research, College of Dentistry, University of Kentucky, Lexington 40536-0305, USA. ogonz2@email.uky.edu
authors.forename: O  A
authors.initials: O
authors.lastname: González
authors.forename: C
authors.initials: C
authors.lastname: Tobia
authors.forename: J  L
authors.initials: J
authors.lastname: Ebersole
authors.forename: M J
authors.initials: MJ
authors.lastname: Novak
mesh_terms: D056704:Adaptive Immunity; D000818:Animals; D032701:Biomimetics; D031204:Caloric Restriction; D002318:Cardiovascular Diseases / Q000178:diet therapy; D002908:Chronic Disease; D003920:Diabetes Mellitus / Q000178:diet therapy; D006801:Humans; D007113:Immunity, Innate; D007249:Inflammation / Q000178:diet therapy*; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors*; D007334:Insulin-Like Growth Factor I / Q000037:antagonists & inhibitors; D008687:Metformin / Q000494:pharmacology; D010518:Periodontitis / Q000178:diet therapy; D000077185:Resveratrol; D015398:Signal Transduction / Q000187:drug effects; D020123:Sirolimus / Q000494:pharmacology; D037761:Sirtuins / Q000187:drug effects; D013267:Stilbenes / Q000494:pharmacology; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors
chemical_list: D018836:Inflammation Mediators; D013267:Stilbenes; D007334:Insulin-Like Growth Factor I; D008687:Metformin; D058570:TOR Serine-Threonine Kinases; D037761:Sirtuins; D000077185:Resveratrol; D020123:Sirolimus